A novel miRNA-762/NFIX pathway modulates LPS-induced acute lung injury

Xiao-Long Zhang1, Jian An2, Yong-Zhi Deng3

  • 1Department of Anesthesiology, Shanxi Cardiovascular Disease Hospital, Taiyuan 030024, China.

Insights

MicroRNAs (miRNAs) like miR-762 play a role in acute lung injury (ALI). Targeting the miR-762/NFIX pathway may offer new therapeutic strategies for ALI.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Immunology

Background:

  • Severe acute lung injury (ALI) is a significant global health concern.
  • MicroRNAs (miRNAs) are emerging as potential biomarkers and therapeutic targets for ALI.
  • The specific role of miR-762 in ALI pathogenesis requires further investigation.

Purpose of the Study:

  • To explore the role of the oncogenic factor miR-762 in the pathogenesis of ALI.
  • To investigate the miR-762/NFIX axis as a potential therapeutic target for ALI.

Main Methods:

  • Measured miR-762 levels in lung tissues of ALI mice and blood cells of ALI patients.
  • Utilized LPS stimulation to induce ALI in human lung epithelial cells (A549) and a mouse model.
  • Employed luciferase reporter assays to validate the interaction between miR-762 and NFIX.
  • Assessed the effects of modulating the miR-762/NFIX axis on cellular processes and inflammatory responses in vitro and in vivo.

Main Results:

  • Upregulation of miR-762 and downregulation of NFIX were associated with lung injury.
  • Inhibition of miR-762 or overexpression of NFIX attenuated LPS-induced lung cell impairment and ALI in mice.
  • Targeting the miR-762/NFIX pathway reduced NF-κB/IRF3 activation and inflammatory factor production (TNF-α, IL-6, IL-8).

Conclusions:

  • The miR-762/NFIX pathway plays a critical role in ALI pathogenesis.
  • Targeting this pathway presents a novel therapeutic strategy for ALI diagnosis, prevention, and treatment.

Related Concept Videos